Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the ADVENT-AML Phase 1B clinical trial abstract was selected for presentation at the 2023 Annual Meeting of the American Society of Hematology (ASH).
The meeting will be held in the US in December.
The company said the presentation highlights the novel design and objectives of the ADVENT-AML clinical trial, the first clinical trial to evaluate its CHM 0201 NK cells in combination with the current standard of care of azacitidine and venetoclax in Acute Myeloid Leukemia patients.
The trial is being conducted at the University of Texas MD Anderson Cancer Center under the direction of principal investigator Dr Abhishek Maiti, Assistant Professor in the Department of Leukemia at MD Anderson.
The trial has received FDA IND and MDACC IRB clearance and is scheduled to begin enrollment in late 2023 with only nominal funding from Chimeric.